Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Dr. Zein Obagi, Founder of ZO Skin Health, Inc., Announces the Launch of ZO® MEDICAL to Raise the Bar in Skin Health Restoration, Which he Launched 25 Years Ago


News provided by

ZO Skin Health, Inc.

Apr 26, 2012, 06:23 ET

Share this article

Share toX

Share this article

Share toX

IRVINE, Calif., April 26, 2012 /PRNewswire/-- On March 17th at the American Academy of Dermatology Annual Meeting, ZO Skin Health, Inc. introduced its new line of medical skin care products, ZO® MEDICAL by Zein Obagi, MD, a therapeutic skin care system developed by world renowned dermatologist Dr. Zein Obagi that will be sold exclusively through physicians' offices both in the United States and in over forty (40) countries internationally.

ZO® MEDICAL is Dr. Zein Obagi's new generation of therapeutic skin care based on his new thinking and reflecting his views on the need to regulate and limit the usage of hydroquinone and retinoic acid for three to five months of treatment. Once therapeutic treatment is complete alternative topical agents should be used. Together with the ZO® SKIN HEALTH line he introduced in 2008, they complete Dr. Zein Obagi's ZO® Skin Health Circle™.  The products have been created to address a wide range of skin disorders and chronic conditions.  With decades of science and experience invested in its development, ZO® MEDICAL by Zein Obagi, MD is suited for everyone, regardless of skin condition, age, gender, or ethnicity.

Dr. Zein Obagi says, "My new line of therapeutic skin care is raising the bar of skin health: a concept I created over 25 years ago and which represents my new thinking of skin health completing my ZO® Skin Health Circle™. It is now a reality."

The ZO® Skin Health Circle™ is an innovative approach focusing on Daily Skincare, Protection, Therapeutic, and Maintenance solutions, which allow patients to achieve continuously healthy skin using today's groundbreaking skin-care protocols, treatments, and products that will enable physicians to retain their patients indefinitely and expand the need for physician services.

Twenty years ago, Dr. Zein Obagi pioneered the concept of skin health and conceived of, and brought to market, a line of medical skincare products – the original Obagi Nu-Derm® System – that transformed aging skin.  Dr. Zein Obagi founded WorldWide Products, which produced and marketed the original Obagi Nu-Derm® System.  At that time, Dr. Zein Obagi merely intended to challenge the norms of traditional skin care.  Instead he shattered the status quo.  Today his ideas about skin health are no longer surprising; they have become mainstream.  Subsequently WorldWide was purchased by Obagi Medical Products, Inc., a company that Dr. Zein Obagi no longer has any affiliation while OMP retained his family name (Obagi®) as their trademark he identified his new line with his full name, Zein Obagi MD.

ZO® MEDICAL b y Zein Obagi, MD includes 11 industry-leading products, with the latest in skin-care technology, including biotechnology complexes, plant stem-cell components, and multi-therapy delivery systems.  Proprietary formulations target pigmentation and discoloration, acne and oily skin, visible signs of skin aging, redness and rosacea, and potent UV protection.  The 11 products, which will soon be available at leading physician offices, include:

  • Normacleanse™: A gentle cleanser for normal to dry skin with collagen-boosting peptides to firm skin.
  • Oilacleanse™: A dual-action cleanser best for normal to oily skin that removes impurities and targets excess oil to prevent clogged pores.
  • Balatone™: A calming toner designed to invigorate dry, weak skin, remove impurities, and balance skin pH.
  • Cebatrol™: Oil control pads that exfoliate with salicylic acid to manage acne, reduce  oiliness, and smooth skin.
  • Glycogent™: A glycolic and lactic acid complex that exfoliates to remove dead skin cells and calms skin with anti-inflammatory antioxidants.
  • Brightenex™: A NEW alternative to  hydroquinone for skin brightening.  A non HQ blend of 1% retinol, melanin inhibitors, and antioxidants brighten and even skin tone.
  • Retamax™: Retinol a in rapid delivery system improves skin tone, texture, and firmness to reverse the signs of aging.
  • Melamin™: Rx-Available by prescription only.  With 4% hydroquinone to inhibit melanin production and correct pigmentation problems in conditions like melasma, freckles, and sun spots.
  • Melamix™: Rx-Available by prescription only.  A skin lightener and blending crème with 4% hydroquinone, a gradual lightening agent.
  • ZO® Controlled Depth Peel™ Kit: For professional use only, the kit when used with TCA 30% treats the skin conditions of acne, wrinkles, fine lines, skin pigmentation disorders, and sun damage (TCA not included).
  • Tretinoin 0.1% and Tretinoin 0.05%: Rx-Available by prescription only.

"ZO® MEDICAL celebrates and personifies my commitment to developing and providing proven, potent, and efficacious solutions for healthy, youthful-looking skin for everyone, no matter what skin condition a patient is facing," says Zein Obagi, MD.

ZO® MEDICAL products will be sold exclusively through physician practices throughout the world. 

You can find more information about ZO® MEDICAL by Zein Obagi, MD and ZO Skin Health, Inc. by visiting www.zoskinhealth.com or by calling Deborah Tomes at (949) 988-7524. 

About Zein Obagi, MD: Researcher, innovator, scientist, published author, lecturer, and board-certified dermatologist, Dr. Zein Obagi has achieved international renown as a leading authority on skin rejuvenation.  Dr. Zein Obagi practices at the Obagi Skin Health Institute in Beverly Hills and the Obagi Skin Health Institute in San Gabriel, California. 

ZO Skin Health, Inc. and Dr. Zein Obagi have no business relationship with Obagi Medical Products, and Obagi Medical Products does not sell or endorse using any ZO® product.  "ZO" is a registered trademark of ZO Skin Health, Inc.  "Obagi" and "Obagi Nu-Derm" are registered trademarks of Obagi Medical Products, Inc. 

SOURCE ZO Skin Health, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Also from this source

ZO® Skin Health Launches Peptide Facial Refining Concentrate to Complement In-Office Procedures. Available Exclusively through Authorized ZO® Providers

ZO® Skin Health Launches Peptide Facial Refining Concentrate to Complement In-Office Procedures. Available Exclusively through Authorized ZO® Providers

ZO® Skin Health, a global leader in medical-grade skincare, has announced the launch of Peptide Facial Refining Concentrate—an advanced peptide serum ...

More Releases From This Source

Explore

Retail

Retail

Cosmetics and Personal Care

Cosmetics and Personal Care

Health Care & Hospitals

Health Care & Hospitals

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.